Data on mRNA vaccines sent by Moderna to European regulators before the COVID-19 outbreak included early tests of the mRNA ...

An image that is spreading widely online claims that Moderna had created its COVID-19 vaccine two years before the pandemic ...

FILE - A local resident receives the Moderna COVID-19 vaccine shot at a center ... CEO Stéphane Bancel said the vaccine maker aims to reduce 2025 cash costs by $1 billion with a plan for an ...

Concerns about the COVID-19 shots have increased after a report that drug maker Moderna failed to inform the U.S. government ...

Established, non-mRNA competition in RSV and influenza could make it difficult for Moderna to gain market share with new vaccines. Moderna's massive covid vaccine sales and prepayments left it ...

Near term, Moderna is expecting the FDA to make a decision on its next-generation COVID shot mRNA-1283 toward the end of May. Beyond that potential nod, the company is working through the ...

CEO Stéphane Bancel said the vaccine maker aims ... its next-generation COVID-19 vaccine, Moderna said. Moderna expects to report data from a trial of its seasonal flu shot this year, if ...

Drug maker Moderna's stock plunged ... The company blamed weak demand for its COVID-19 vaccine shots and a slow launch of a new RSV vaccine. Moderna announced that it hopes to reduce costs by ...

Pfizer's fourth quarter beat expectations on strong sales of its Covid vaccine and pill, bolstering its sales as it seeks to ...

CEO Stéphane Bancel said the vaccine maker aims ... its next-generation COVID-19 vaccine, Moderna said. Moderna expects to report data from a trial of its seasonal flu shot this year, if ...

Demand for its COVID vaccine has been waning since the pandemic, while adoption of its RSV shot - its second approved product- has been slower than expected, forcing Moderna to cut costs.